Hjem › Leverkreft (hepatocellulært karcinom) › Pennsylvania › Pittsburgh
Kliniske studier for Leverkreft (hepatocellulært karcinom) i Pittsburgh, PA
15 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i og rundt Pittsburgh (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RekruttererFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #32, Pittsburgh
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RekruttererFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RekruttererFase 3
- Research Site, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Molecular Basis of Pediatric Liver Cancer
RekruttererObservasjonsstudie
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RekruttererFase 2
- Allegheny General Hospital, Pittsburgh
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RekruttererFase 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RekruttererFase 1
- Clinical Trial Site, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RekruttererFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RekruttererFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
RekruttererFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RekruttererFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Leverkreft (hepatocellulært karcinom)-studier i andre byer
- Houston, TX31 studier
- New York City, NY24 studier
- Dallas, TX19 studier
- Los Angeles, CA19 studier
- Boston, MA18 studier
- Cleveland, OH18 studier
- Chicago, IL16 studier
- Philadelphia, PA16 studier
- San Francisco, CA14 studier
- Orange, CA14 studier
- Jacksonville, FL14 studier
- San Antonio, TX13 studier
Andre studier i Pittsburgh
- Ikke-småcellet lungekreft48 studier
- Kreft (alle typer)41 studier
- Brystkreft39 studier
- Kolorektal kreft32 studier
- Metastatisk kreft31 studier
- Melanom31 studier
- Eggstokkreft30 studier
- Endometriekreft23 studier
- Prostatakreft23 studier
- Lungekreft23 studier
- Plateepitelcancer i hode og hals22 studier
- Slag22 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.